Ellagic acid protects against non-alcoholic fatty liver disease in streptozotocin-diabetic rats by activating AMPK

Abstract

These findings encourage the use of EA to treat hepatic disorders, and non-alcoholic fatty liver disease (NAFLD). Further <i>in vivo</i> and <i>in vitro</i> studies are needed to validate its potential in clinical medicine.